TrialCancer immunology, immunotherapy : CII2019

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Alberto A Chiappori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.